Zymeworks BC Inc
Zymeworks BC Inc (ZYME) Wheel Strategy
ZYME wheel strategy scan found 6 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 45.3%.
Read more
Running a ZYME wheel strategy lets you generate consistent premium income on Zymeworks BC Inc while setting your own entry and exit prices on the underlying. Zymeworks BC Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own ZYME, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best ZYME wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on ZYME, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable ZYME wheel from a losing one.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc.
It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the ZYME wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your ZYME wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
| Nov 20, 2026 | 25.00 | $0.20 | $1.80 | -0.31 | 58 | 13% | 63.2% | 45.3% | 29 |
| Oct 16, 2026 | 25.00 | $0.40 | $0.60 | -0.23 | 23 | 13% | 73.2% | 38.1% | 2,588 |
| Jan 15, 2027 | 25.00 | $0.45 | $2.73 | -0.32 | 114 | 13% | 57.2% | 34.9% | 182 |
| Apr 16, 2027 | 25.00 | $0.70 | $3.10 | -0.31 | 205 | 13% | 52.6% | 22.1% | 135 |
| Apr 16, 2027 | 22.50 | $0.20 | $2.55 | -0.24 | 205 | 13% | 62.3% | 20.2% | 0 |
| Dec 17, 2027 | 22.50 | $1.00 | $3.50 | -0.24 | 450 | 13% | 53.2% | 12.6% | 0 |
As of September 23, 2026
Run the Wheel on ZYME With Confidence
Find the best ZYME wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.
Start your 14-day free trial→